EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Shu Cui, Xiongfei Luo, Guangrui Fan, Jingqi Jiang, Yingru Wang, Enguang Yang, Jinpeng Ma, Ze Zhang, Yuhan Wang, Juan Wang, Dengtuo Wang, Hanzhang Wang und 5 weitere

Advanced Science · 2026-01 · 13 (4)

DOI: 10.1002/advs.202509933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.10.2025. Verfasst von Shu Cui und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Urology, The Second Hospital of Lanzhou University, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, 730030,…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Apoptosis, Receptor, Fibroblast Growth Factor, Type 3, Immunoconjugates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gansu Province Major Science and Technology Special Project, Key Research and Development Program of Gansu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) emerge as a potent cancer therapeutic strategy by enabling precise antigen recognition and efficient intracellular delivery of cytotoxic payloads. In this study, 7‐ethyl‐9‐fluorocamptothecin (A2), a camptothecin derivative, which demonstrates potent tumor‐suppressive effects across cellular models, patient‐derived organoids (PDOs), and cell line‐derived xenograft/patient‐derived xenograft (CDX/PDX) models is identified. Through pull‐down/mass spectrometry analysis, MAD2L1 is identified as the direct target of A2. A2 specifically binds to the Lys73 site of MAD2L1, activating the cGAS‐STING pathway and thereby inducing apoptosis in bladder cancer cells. To address the dose‐limiting toxicity caused by A2's insufficient targeting capability, LZU‐WZLYCS01, a novel FGFR3‐targeting ADC for bladder cancer with A2 as its cytotoxic payload is developed. LZU‐WZLYCS01 exhibits precise FGFR3‐dependent targeting, with significantly reduced antitumor activity in both FGFR3‐knockout cell models and xenograft models. Moreover, in vivo fluorescence imaging demonstrates the potent tumor‐targeting capability of LZU‐WZLYCS01. LZU‐WZLYCS01 demonstrates remarkable bystander effects in an in vitro co‐culture model, along with potent tumor growth inhibition in PDOs and CDX/PDX models while maintaining favorable safety. Notably, LZU‐WZLYCS01 shows superior antitumor efficacy to gemcitabine‐cisplatin (GC) chemotherapy and maintains significant activity in GC‐resistant PDX models. These findings present a promising therapeutic candidate for targeted bladder cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsApoptosisReceptor, Fibroblast Growth Factor, Type 3ImmunoconjugatesNucleotidyltransferasesMembrane ProteinsHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysSignal TransductionSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Stichwörter der Autor:innen

7‐ethyl‐9‐fluorocamptothecinMAD2L1antibody‐drug conjugatesbladder cancercGAS‐STING

Substanzen

Receptor, Fibroblast Growth Factor, Type 3ImmunoconjugatesNucleotidyltransferasesMembrane ProteinsFGFR3 protein, humancGAS protein, humanSTING1 protein, humanSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Autor:innen und Institutionen

  • Institute of Urology, The Second Hospital of Lanzhou University, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, 730030, China.
  • School of Pharmacy, Lanzhou University, Lanzhou, 730030, China.
  • Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
  • The Legorreta Cancer Center at Brown University, Department of Pathology and Laboratory Medicine, The Warren Albert Medical School of Brown University, Brown University Health, Providence, RI, USA.

ORCID-Profile: Zhiping Wang

Förderung

  • National Natural Science Foundation of China
  • Gansu Province Major Science and Technology Special Project
  • Key Research and Development Program of Gansu Province

Zitieren

APA

Cui, S., Luo, X., Fan, G., Jiang, J., Wang, Y., Yang, E., Ma, J., Zhang, Z., Wang, Y., Wang, J., Wang, D., Wang, H., Cheng, L., Tian, J., Dong, Z., Liu, Y., & Wang, Z. (2026). A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer. Advanced Science, 13(4). https://doi.org/10.1002/advs.202509933

Vancouver

Cui S, Luo X, Fan G, Jiang J, Wang Y, Yang E, et al. A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer. Advanced Science. 2026;13(4). doi:10.1002/advs.202509933

BibTeX
@article{Cui2026,
  author = {Cui, Shu and Luo, Xiongfei and Fan, Guangrui and Jiang, Jingqi and Wang, Yingru and Yang, Enguang and Ma, Jinpeng and Zhang, Ze and Wang, Yuhan and Wang, Juan and Wang, Dengtuo and Wang, Hanzhang and Cheng, Liang and Tian, Junqiang and Dong, Zhilong and Liu, Yingqian and Wang, Zhiping},
  title = {A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {4},
  doi = {10.1002/advs.202509933}
}
Kostenlos starten →